The number of patients treated for tuberculosis after undergoing spine surgery with FiberCel, a bone matrix allograft, is growing.

Ortho Regenerative Technologies named Howard Walthall and Tim Cunningham to its board of directors, the company said June 15.

The FDA is ramping up enforcement activities against companies developing unapproved stem cell therapies, particularly for spine and orthopedic indications, according to the Regulatory Affairs Professional Society.

Ortho Regenerative Technologies received a clinical hold letter from the FDA related to its trial for its hybrid implant, Ortho-R, the company said June 4.

Adipose cells, commonly known as fat, could be a useful source of stem cells to promote bone growth in spinal fusion, according to researchers from Johns Hopkins Medicine in Baltimore.

The FDA has granted breakthrough device designation for Cerapedics' P-15L bone graft for the treatment of degenerative disc disease.

DiscGenics, a biopharmaceutical company focused on regenerative therapies for spinal conditions, has finished enrolling patients in its Japanese study of  IDCT, an allogeneic, injectable disc cell therapy for lumbar disc degeneration.

Pacira Biosciences invested $3 million in Spine BioPharma.

Rishi Wadhwa, MD, of Shreveport, La.-based Specialists Hospital, completed the first implantation of Ventris Medical's Allocell AF allograft.

Orthobiologics company Kuros Biosciences has treated the first patient in a clinical trial comparing MagnetOs Putty to autograft for posterolateral spinal fusion.

The first two spinal surgery cases with TheraCell's TheraFuze DBF Fiber Bag were completed in Illinois and Texas.

Two professors from West Lafayette, Ind.-based Purdue University developed a shoulder implant that uses a patient's stem cells to help repair the rotator cuff.

From studies advancing spine treatment to new techniques in stem cell procedures, here are seven updates on biologics so far this year:

The global regenerative medicine market is projected to reach $39 million by 2030, up from $8.2 million in 2019, according to market research company P&S Intelligence.

Orthopedic biotechnology company Ortho Regenerative Technologies focused on developing soft tissue repair regenerative technology in 2020. For 2021, that development is expected to grow.

UC Davis Health in Sacramento, Calif., on March 1 announced the launch of the first FDA-approved human clinical trial using stem cells before birth to treat spina bifida, a defect that occurs when the spine and spinal cord do not form properly.

Patients injected with stem cells derived from their own bone marrow saw improvement in motor functions after spinal cord injuries, a study from New Haven, Conn.-based Yale University found.

Butte-based Montana Orthopedics' Anthony Russo, MD, became the first spine surgeon in the U.S. to implant Kore Fiber, a demineralized cortical fiber allograft.

DiscGenics, a biopharmaceutical company focused on regenerative therapies for spinal conditions, has completed construction on its 25,000-square-foot headquarters in Salt Lake City.

Orthobiologics company Bioventus launched its initial public offering, according to a Feb. 4 news release.